CooperCompanies (NYSE: COO) today announced that it has signed a definitive purchase agreement to acquire Generate Life Sciences, a privately held leading provider of donor egg and sperm for fertility treatments, fertility cryopreservation services and newborn stem cell storage (cord blood & cord tissue).
“This acquisition is a strong strategic fit for CooperSurgical as it allows us to better serve fertility clinics and Ob/Gyns with a more extensive suite of products and services,” said Al White, Cooper’s President and CEO. “As a leader in women’s healthcare, this is an important addition to our existing offerings and allows us to leverage our infrastructure and expertise, including our sales forces’ strong clinical reputation and educational capabilities.”
Cooper will pay approximately $1.6 billion to acquire Generate Life Sciences. The transaction is anticipated to close in Cooper’s first fiscal quarter of 2022 and is subject to customary closing conditions, including regulatory approval.
Generate Life Sciences reported approximately $250 million in trailing twelve-month revenues as of September 30, 2021. Excluding one-time charges and deal-related amortization, the acquisition is expected to be accretive to Cooper’s non-GAAP earnings per share by approximately $0.30 in the first year after closing.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Additional details concerning the acquisition are available in a presentation on the Investor Relations section of Cooper’s website at http://investor.coopercos.com under the presentation titled “Generate Life Sciences.”
Source: Biospace
